Drugs / NoNO-42
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05636306 | Nov 2022 → Oct 2023 | — | NoNO Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06352632 | Sep 2024 → Sep 2034 expected | stroke disorder | The George Institute | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06403267 Comparator | Oct 2024 → Dec 2026 expected | ischemic stroke | NoNO Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NoNO-42 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05636306 ↗ |
| Route | Intravenous | “single ascending intravenous dose of NoNO-42 administered to healthy adults” NCT05636306 ↗ |